Interferon α therapy in patients with chronic hepatitis C infection. Biopsychosocial consequences;Interferon α bei patienten mit chronischer hepatitis c: Biopsychosoziale auswirkungen

Nervenarzt

Volumn 83, Issue 9, 2012, Pages 1169-1177

  Baranyi, A ^a   Meinitzer, A ^a   Stepan, A ^a   Matejka, J ^a   Stauber, R ^a   Kapfhammer, H P ^a   Rothenhausler H B ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cognitive functioning; Depressive disorder; Hepatitis C; Interferon alpha; Quality of life

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; DEPRESSION; HAMILTON SCALE; HEPATITIS C; HUMAN; LIFE SATISFACTION; MENTAL HEALTH; QUALITY OF LIFE; RATING SCALE; SELF CONCEPT; SHORT FORM 36; SOCIAL INTERACTION; SOCIAL SUPPORT; SOCIAL SUPPORT QUESTIONNAIRE; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DEPRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84866938898     PISSN: 00282804     EISSN: 14330407     Source Type: Journal    
DOI: 10.1007/s00115-011-3302-y     Document Type: Article

References (30)

1. Baranyi A, Rothenhäusler HB (2005) Interferon-alpha-induzierte Depressionen bei Patienten mit chronischen Hepatitis-C-Infektionen. Psychiatr Psychother 1(2):51-55
2. Bonaccorso S, Marino V, Biondi M et al (2002) Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 72:237-241
3. Bonaccorso S, Marino V, Puzella A et al (2002) Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 22:86-90
4. Bullinger M, Kirchberger I (1995) Der SF-36-Fragebogen zum Gesundheitszustand. Hogrefe, Göttingen Bern Toronto Seattle
5. Crone C, Gabriel GM (2003) Comprehensive review of hepatitis C for psychiatrists: Risk, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract 9:93-110
6. Dieperink E, Willenbring M, Ho S (2000) Neuropsychiatric symptoms associated with hepatitis c and interferon-alpha: a review. Am J Psychiatry 157:867-876
7. Donald CA, Ware JE (1984) The measurement of social support. Res Commun Ment Health 4:325-370
8. Erzigkeit H (1989) SKT - Ein Kurztest zur Erfassung von Gedächtnis- und Aufmerksamkeitsstörungen. Beltz, Weinheim
9. Fahrenberg J, Myrtek M, Schuhmacher J et al (2000) Fragebogen zur Lebenszufriedenheit (FLZ) Handanweisung. Hogrefe, Göttingen Bern Toronto Seattle
10. Fontana RJ, Moyer CA, Sonnad S et al (2001) Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol 96:170-180
11. Golub ET, Latka M, Hagan H et al (2004) Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the beck depression inventory. J Urban Health 81:278-290
12. Grammatikos G, Sarrazin C (2010) Chronic hepatitis C. Dtsch Med Wochenschr 135(50):2525-2534
13. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Clin Psychol 6:278-296
14. Hautzinger M, Bailer M, Worall W et al (1995) BDI Beck-Depressions- Inventar. (2. überarb. Aufl.). Hogrefe, Göttingen Bern Toronto Seattle
15. Hilsabeck RC, Hassanein TI, Tarek et al (2003) Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 9:847-854
16. Hnatyszyn HJ (2005) Chronic hepatitis C and genotyping: the clinical significance of determing HCV genotypes. Antivir Ther 10:1-11
17. Kirchberger J, Bullinger M (1998) Der Social Support Fragebogen. Hogrefe, Göttingen, Bern, Toronto, Seattle
18. Leutscher PD, Lagging M, Buhl MR et al (2010) Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 52(2):430-435
19. Malaguarnera M, Laurino A, Di Fazio I et al (2001) Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res 21:273-278
20. Pierucci-Lagha A, Covault J, Bonkovsky HL et al (2010) A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics 51(2):137-148
21. Poutiainen E, Hokkanen L, Niemi M et al (1994) Reversible cognitive decline during high dose alpha-interferon treatment. Pharmacol Biochem Behavior 47:901-905
22. Rothenhäusler HB, Scherr M, Putz-Bankutti C et al (2009) Der Zusammenhang zwischen emotionalen Befindlichkeitsstörungen, kognitiver Leistungsfähigkeit und gesundheitsbezogener Lebensqualität bei mit dem Hepatitis-C-Virus infizierten Patienten vor einer antiviralen Therapie. Fortschr Neurol Psychiatr 77:457-463
23. Schäfer M (2002) Neuro-psychiatrische Nebenwirkungen von Interferon-alpha bei Drogenabhängigen: Ursachen, Häufigkeit und Therapie. Suchttherapie (Suppl 3):572-577
24. Schäfer M, Schwaiger M (2003) Interferon-alpha assoziierte psychische Nebenwirkungen. Fortschr Neurol Psychiatr 71:469-476
25. Schäfer M (2005) Therapie der chronischen Hepatitis C bei Patienten mit psychischen Erkrankungen. Suchttherapie 6:66-69
26. Stauber RE, Kessler HH (2008) Drugs in development for hepatitis C. Drugs 68:1347-1359
27. Stein MD, Solomon DA, Herman DS et al (2003) Depression severity and drug injection - HIV risk behaviours. Am J Psychiatry 160:1659-1662
28. Turner EH, Blackwell AD (2005) 5-Hydroxytryptophan plus SSRI for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotonin. Med Hypotheses 65:138-144
29. Stewart AL, Hays RD, Ware JE (1988) The MOS Short-form General Health Survey: reliability and validity in a patient population. Med Care 26:724-735
30. Wichers MC, Koeck GH, Robaeys G et al (2005) IDO and interferon-alpha- induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 10:538-544